Compound Detail
CHEMBL294951
PIZOTYLINE 🧪 Phase II
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
🧪 Phase II
Basic Information
| ChEMBL ID | CHEMBL294951 |
| Name | PIZOTYLINE |
| Phase | Phase II |
| Structure Type | MOL |
| InChI Key | FIADGNVRKBPQEU-UHFFFAOYSA-N |
11
Targets
12
Activities
2
Assay Types
0
PK Parameters
20
Publications
6
Known Names
1
Indications
Molecular Properties
295.4
MW (Da)
4.37
ALogP
2
HBA
0
HBD
3.2
PSA (Ų)
0.70
QED
0
Ro5 Violations
0
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| Chirality | Achiral |
Indications
Migraine Disorders
ATC Classification
N02CX01
pizotifen
Level 1: NERVOUS SYSTEM
Level 2: ANALGESICS
Activity Summary
Ki 7 meas. best 8.85
IC50 5 meas. best 5.73
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 2C CHEMBL225 | Ki | 8.85 | 8.85 | 1.4 | 1 |
| 5-hydroxytryptamine receptor 2B CHEMBL1833 | Ki | 8.7 | 8.7 | 2.0 | 1 |
| Muscarinic acetylcholine receptor M1 CHEMBL216 | Ki | 8.7 | 8.7 | 2.0 | 1 |
| D(2) dopamine receptor CHEMBL217 | Ki | 8.62 | 8.62 | 2.4 | 1 |
| 5-hydroxytryptamine receptor 2A CHEMBL224 | Ki | 8.12 | 8.12 | 7.5 | 1 |
| 5-hydroxytryptamine receptor 7 CHEMBL3155 | Ki | 7.6 | 7.6 | 25.0 | 1 |
| Adrenergic receptor alpha-1 CHEMBL2094251 | Ki | 7.12 | 7.12 | 75.0 | 1 |
| Plasmodium falciparum CHEMBL364 | IC50 | 5.73 | 5.73 | 1860.0 | 1 |
| Trypanosoma brucei rhodesiense CHEMBL612348 | IC50 | 5.4 | 5.4 | 3990.0 | 1 |
| Trypanosoma cruzi CHEMBL368 | IC50 | 4.51 | 4.51 | 30630.0 | 1 |
| NON-PROTEIN TARGET CHEMBL3879801 | IC50 | 4.35 | 4.35 | 45020.0 | 1 |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| 22194678 | 10.1371/journal.pcbi.1002310 | Hepatotoxicity | 14 |
| 15646539 | 10.1016/s0399-8320(04)95062-2 | Unchecked | 11 |
| 15646539 | 10.1016/s0399-8320(04)95062-2 | NON-PROTEIN TARGET | 8 |
| 37468498 | 10.1038/s41467-023-40064-9 | 5-hydroxytryptamine receptor 2A | 3 |
| 20014752 | 10.1021/tx900326k | Hepatotoxicity | 3 |
| 37468498 | 10.1038/s41467-023-40064-9 | Cannabinoid receptor 1 | 3 |
| 37468498 | 10.1038/s41467-023-40064-9 | Alpha-2A adrenergic receptor | 3 |
| 37468498 | 10.1038/s41467-023-40064-9 | Muscarinic acetylcholine receptor M2 | 3 |
| 37468498 | 10.1038/s41467-023-40064-9 | Histamine H1 receptor | 3 |
| 37468498 | 10.1038/s41467-023-40064-9 | Alpha-1A adrenergic receptor | 3 |
| - | 10.6019/CHEMBL4808148 | Histone deacetylase 6 | 2 |
| - | 10.6019/CHEMBL4651402 | SARS-CoV-2 | 2 |
| - | 10.6019/CHEMBL3392926 | Leishmania donovani | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Beta-2 adrenergic receptor | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Gamma-aminobutyric acid receptor subunit alpha-1 | 2 |
| - | 10.6019/CHEMBL3392926 | NON-PROTEIN TARGET | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | 5-hydroxytryptamine receptor 1A | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | 5-hydroxytryptamine receptor 2B | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | D(1A) dopamine receptor | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Gamma-aminobutyric acid receptor subunit alpha-1/alpha-2/beta-2/gamma-2 | 2 |
Data from ChEMBL 36 via Core Engine